九洲药业子公司获得甲苯磺酸艾多沙班药品注册证书

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received approval from the National Medical Products Administration for the registration of Tofisopam Tosylate Tablets, marking a significant milestone for the company in the oral anticoagulant market [1] Group 1: Company Developments - Jiuzhou Pharmaceutical's wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has been granted the Drug Registration Certificate for Tofisopam Tosylate Tablets [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Industry Context - Tofisopam Tosylate was originally developed by Daiichi Sankyo in Japan and was launched in April 2011 [1] - Other manufacturers in China that have obtained registration for this drug include Hainan Xiansheng Pharmaceutical Co., Ltd. and Shandong New Era Pharmaceutical Co., Ltd. [1]